The burgeoning landscape of treatment for weight management and type 2 diabetes is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant variations in their pharmacological profiles and clinical study results are emerging. Retatrutide, bo

Retaglutide and tirzepatide represent innovative category of medications known as dual GLP-1 and GIP agonists. These agents regulate both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic more info polypeptide (GIP), two hormones that perform a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, th